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Background
H1 receptor antagonists are widely used drugs for treat-
ment of allergic conditions. While histamine is involved
in bone remodelling [1-3], the aim of this study was to
determine the effects of cetirizine, an H1 receptor antago-
nist, on bone modeling processes during orthodontic
tooth movement.
Methods
We used three groups of Wistar rats: control group (n =
16), orthodontic appliance only group (n = 16) and ceti-
rizine group (n = 16). Animals of the last two groups were
fitted with a super-elastic closed coil spring appliance (F =
25 cN) between the upper first left molar and the upper
incisors. Animals of the appliance only group were treated
daily with saline and animals of the cetirizine group with
3 mg/kg of cetirizine, respectively. Tooth movement was
measured weekly from day 0 to day 42. Animals of each
group were sacrificed on day 42 and tissue samples were
prepared for further analysis. Gene expression levels for
bone turnover markers cathepsin K and osteocalcin were
determined by means of RT-PCR. Alveolar bone volume,
osteoblast and osteoclast volume were determined histo-
morphometrically.
Results
Cetirizine decreased the amount of tooth movement from
day 28 onwards (p < 0.01) and it also decreased osteoclast
volume (p < 0.001). The increase in the alveolar bone vol-
ume was observed in the cetirizine group (p < 0.01) com-
pared to the appliance only group. No significant
difference was observed in osteoclast activity, osteoblast
volume and osteoblast activity between the cetirizine and
the appliance only groups.
Conclusion
Cetirizine influences bone modeling, mainly by inhibit-
ing bone resorption. Therefore, H1 receptor antagonists
therapy is supposed to interfere with orthodontic treat-
ment.
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